Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
In Japan, revisions to selling prices reflecting higher raw material and labor costs, increased order and sales volumes, and improved profitability contributed to results. In China, order volumes from existing customers continued to decline due to lower pharmaceutical sales to the United States and Chinese administrative authorities' procurement policy for low-priced pharmaceuticals.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥9,192 million (YoY +6.5%) |
| Operating profit | ¥299 million (YoY +1.0%) |
| Ordinary income | ¥305 million (YoY -7.1%) |
| Profit attributable to owners of the parent | ¥200 million (YoY -11.2%) |
| Total assets | ¥20,261 million |
| Net assets | ¥11,463 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Remarks Unchanged from the forecast announced on 9 February 2026 |
| Revision to Earnings Forecast | No change |
| Segment revenue | Japan ¥8,026 million (YoY +7.4%), China ¥1,561 million (YoY -3.4%) |
| Segment profit | Japan ¥529 million (YoY +47.6%), China ¥-84 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Factors Behind Changes in Business Performance | In Japan, revisions to selling prices reflecting higher raw material and labor costs, increased order and sales volumes, and improved profitability contributed to results. In China, order volumes from existing customers continued to decline due to lower pharmaceutical sales to the United States and Chinese administrative authorities' procurement policy for low-priced pharmaceuticals. |
Items this document does not state (22)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, in addition to revisions to selling prices reflecting higher raw material and labor costs, order volumes and sales volumes increased, while improved profitability also contributed. In China, order volumes from existing customers continued to decline, but the impact was absorbed by higher sales volumes and improved profitability in Japan.